New England Journal of Medicine November 16, 1995

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

James Shepherd, Stuart M. Cobbe, Ian Ford, Christopher G. Isles, A. Ross Lorimer, Peter W. MacFarlane, James H. McKillop, Christopher J. Packard

Source: View publication →

Bottom Line

The WOSCOPS trial was a landmark randomized controlled study demonstrating that treating middle-aged men with hypercholesterolemia and no history of myocardial infarction with pravastatin significantly reduced the risk of first major coronary events.

Key Findings

1. Pravastatin treatment lowered plasma total cholesterol levels by 20% and low-density lipoprotein (LDL) cholesterol by 26%.

2. The primary composite endpoint (definite nonfatal myocardial infarction or coronary heart disease death) was significantly reduced, occurring in 7.9% of the placebo group versus 5.5% of the pravastatin group (relative risk reduction 31%, P<0.001) [2.1.3].

3. The rate of death from coronary heart disease was reduced from 1.9% in the placebo group to 1.3% in the pravastatin group (P=0.042).

4. All-cause mortality was lower in the pravastatin group (3.2%) compared to the placebo group (4.1%), falling just short of statistical significance (P=0.051).

5. The need for coronary revascularization procedures (coronary-artery bypass grafting or percutaneous transluminal coronary angioplasty) was reduced by 37% in the pravastatin group (P=0.009).

Study Design

Design

RCT

Double-Blind

Sample

6,595

Patients

Duration

4.9 yr

Median

Setting

West of Scotland

Population Men aged 45 to 64 years with hypercholesterolemia (mean plasma cholesterol level of 272 mg/dL) and no history of myocardial infarction.

Intervention Pravastatin 40 mg once daily.

Comparator Placebo once daily.

Outcome Composite of definite nonfatal myocardial infarction or death from coronary heart disease.

Study Limitations

• The trial enrolled exclusively middle-aged men of European descent from a single geographic region, limiting the immediate generalizability of the findings to women, older adults, and other ethnic populations.

• The study evaluated a fixed, single-dose regimen of a moderate-intensity statin (pravastatin 40 mg), not addressing the comparative efficacy of titrated or high-intensity statin therapy.

• Although there was a strong trend toward reduced all-cause mortality, it did not achieve statistical significance at the conventional P<0.05 threshold during the initial 4.9-year trial period.

• The baseline cardiovascular risk of the West of Scotland population in the early 1990s was exceptionally high, meaning the absolute risk reductions observed might be smaller in modern, lower-risk primary prevention cohorts.

Clinical Significance

WOSCOPS was a paradigm-shifting trial that provided the first definitive evidence that lowering LDL cholesterol with a statin in a primary prevention population could safely and effectively reduce the incidence of major coronary events and coronary mortality. By expanding the proven benefits of statins beyond patients with established cardiovascular disease (as shown previously in the 4S trial), WOSCOPS radically transformed cardiovascular practice guidelines, establishing statin therapy as a cornerstone of primary cardiovascular disease prevention in high-risk individuals.

Historical Context

Prior to WOSCOPS, the value of lipid-lowering therapy in individuals without clinical coronary heart disease was a subject of intense medical controversy. Earlier primary prevention trials using diet, clofibrate, or cholestyramine had shown modest reductions in nonfatal cardiovascular events but failed to demonstrate a survival benefit, and some raised concerns about potential increases in non-cardiovascular mortality. Following the 1994 publication of the 4S trial, which proved statins were life-saving in secondary prevention, WOSCOPS answered the critical question of whether these profound benefits extended to primary prevention, permanently altering the landscape of preventive cardiology.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does pravastatin pharmacologically reduce LDL cholesterol, and why was primary prevention in this specific patient population (men with high cholesterol but no previous MI) a critical next step after earlier statin trials?

Key Response

Pravastatin is an HMG-CoA reductase inhibitor, decreasing hepatic cholesterol synthesis and upregulating LDL receptors. WOSCOPS was vital because earlier trials (like 4S) only proved statins worked in patients who already had an MI (secondary prevention). WOSCOPS proved they prevent the first heart attack.

Resident

Based on the WOSCOPS criteria, how would we stratify this patient population using modern ASCVD risk calculators, and would current guidelines still recommend a moderate-intensity statin like pravastatin 40 mg for them?

Key Response

The men in WOSCOPS had high LDLs (often >190 mg/dL) and high baseline risk (smokers, hypertension). Today, many would qualify for high-intensity statins (e.g., atorvastatin 40-80mg or rosuvastatin 20-40mg) either due to LDL > 190 mg/dL or a high 10-year ASCVD risk score, rather than the moderate-intensity pravastatin used in the 1990s.

Fellow

WOSCOPS demonstrated a significant reduction in coronary events but only a trend toward reduced all-cause mortality during the initial trial period. How do we reconcile this with the long-term legacy effect seen in the 20-year follow-up of the WOSCOPS cohort?

Key Response

While the 5-year data showed a reduction in all-cause mortality that was borderline significant, the 20-year observational follow-up revealed a sustained mortality benefit (the legacy effect). This suggests early plaque stabilization and lipid lowering alter the long-term trajectory of atherosclerotic disease even after the trial ends.

Attending

Before WOSCOPS, there was concern that pharmacologically lowering cholesterol might increase non-cardiovascular mortality, such as cancer or suicide. How did WOSCOPS definitively shift the paradigm of primary prevention risk-benefit discussions in practice?

Key Response

Earlier lipid-lowering trials using fibrates or resins showed concerning signals for violent deaths or cancer, leading to reluctance in treating asymptomatic patients. WOSCOPS showed no increase in non-cardiovascular deaths with pravastatin, reassuring physicians that statin therapy was safe for primary prevention and fundamentally changing the threshold for prescribing.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The WOSCOPS trial enrolled exclusively middle-aged men from the West of Scotland, a region known at the time for exceptionally high cardiovascular event rates. How does this epidemiological context affect the generalizability of the absolute risk reduction to contemporary, diverse populations?

Key Response

The high baseline risk inflated the absolute risk reduction (ARR) and lowered the Number Needed to Treat (NNT). In modern cohorts with lower baseline incidence of ASCVD (due to less smoking, better BP control), the relative risk reduction remains similar, but the ARR is smaller, making cost-effectiveness and NNT highly dependent on accurate baseline risk estimation.

Journal Editor

If reviewing this manuscript today, how would you critically evaluate the lack of female representation in the study cohort, and what methodological justifications or flaws does this introduce regarding the applicability of the primary prevention conclusion?

Key Response

A major limitation is the exclusion of women. The investigators likely did this to maximize statistical power, as women in that age group have lower baseline CHD event rates. A modern reviewer would flag this as a critical threat to external validity, requiring subsequent trials (like JUPITER) to confirm primary prevention efficacy in women.

Guideline Committee

WOSCOPS established the efficacy of statins in primary prevention, but current ACC/AHA guidelines heavily emphasize the 10-year ASCVD risk score rather than isolated hypercholesterolemia (unless LDL > 190 mg/dL). How did WOSCOPS inform the evolution from purely lipid-target based guidelines to risk-based guidelines?

Key Response

WOSCOPS showed that the absolute benefit of statins depends on the underlying global cardiovascular risk, not just the baseline LDL level. This foundational evidence eventually guided the 2013 ACC/AHA shift away from strict LDL targets toward matching statin intensity to a patient's overall 10-year ASCVD risk, reserving automatic treatment for those with severe hypercholesterolemia.

Clinical Landscape

Noteworthy Related Trials

1994

Scandinavian Simvastatin Survival Study (4S)

n = 4,444 · Lancet

Tested

Simvastatin 20-40 mg daily

Population

Patients with angina pectoris or previous MI and high serum cholesterol

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Simvastatin significantly reduced all-cause mortality by 30% and coronary mortality by 42% over a median follow-up of 5.4 years.

1998

AFCAPS/TexCAPS

n = 6,605 · JAMA

Tested

Lovastatin 20-40 mg daily

Population

Men and women without symptomatic cardiovascular disease with average LDL and below-average HDL

Comparator

Placebo

Endpoint

First acute major coronary event

Key result: Lovastatin reduced the risk of first acute major coronary events by 37% in a relatively low-risk primary prevention cohort.

2008

JUPITER Trial

n = 17,802 · NEJM

Tested

Rosuvastatin 20 mg daily

Population

Healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein

Comparator

Placebo

Endpoint

First major cardiovascular event

Key result: Rosuvastatin significantly reduced the incidence of major cardiovascular events by 44% in healthy persons with elevated hsCRP.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis